# Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

> **NCT00327262** · PHASE3 · UNKNOWN · sponsor: **Central European Leukemia Study Group** · enrollment: 240 (—)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00327262
- **Lead sponsor:** Central European Leukemia Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 240 (—)
- **Last updated:** 2006-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327262, "Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00327262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*